Breaking Finance News

A statement released earlier today by Gabelli about Clovis Oncology (NASDAQ:CLVS) raises the target price to $125.00

Clovis Oncology (NASDAQ:CLVS) had its target bumped up to $125.00 by Gabelli in an issued report issued Friday July 07, 2017. The upped price target implies a potential upside of 0.35% from the company's most recent close.

Boasting a price of $92.78, Clovis Oncology (NASDAQ:CLVS) traded 2.01% higher on the day. With the last close up 5.84% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. Clovis Oncology has recorded a 50-day average of $87.18 and a two hundred day average of $67.07. Volume of trade was down over the average, with 1,287,020 shares of CLVS changing hands under the typical 1,968,820

Performance Chart

Clovis Oncology (NASDAQ:CLVS)

With a market capitalization of $0, Clovis Oncology has 52 week low of $16.58 and a 52 week high of $99.45 .

In addition to Gabelli reporting its target price, a total of 8 brokers have issued a report on the stock. The consensus target price is $17.50 with two equity analysts rating the company a strong buy, zero firms rating the stock a buy, 6 firms rating the stock a hold, zero analysts rating the company a underperform, and lastly zero brokers rating the stock a sell.

General Information About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *